JP2005513165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005513165A5 JP2005513165A5 JP2003557558A JP2003557558A JP2005513165A5 JP 2005513165 A5 JP2005513165 A5 JP 2005513165A5 JP 2003557558 A JP2003557558 A JP 2003557558A JP 2003557558 A JP2003557558 A JP 2003557558A JP 2005513165 A5 JP2005513165 A5 JP 2005513165A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- optionally substituted
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 55
- 125000003118 aryl group Chemical group 0.000 claims 46
- 125000001072 heteroaryl group Chemical group 0.000 claims 43
- 125000000753 cycloalkyl group Chemical group 0.000 claims 35
- 125000003342 alkenyl group Chemical group 0.000 claims 20
- 125000000304 alkynyl group Chemical group 0.000 claims 19
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 17
- 229910052799 carbon Inorganic materials 0.000 claims 17
- -1 N- (substituted glycyl) -4-cyanopyrrolidine Chemical class 0.000 claims 16
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 9
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 102000003729 Neprilysin Human genes 0.000 claims 5
- 108090000028 Neprilysin Proteins 0.000 claims 5
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims 4
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- 206010016807 Fluid retention Diseases 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- ZTWZVMIYIIVABD-OEMFJLHTSA-N candoxatril Chemical group C([C@@H](COCCOC)C(=O)OC=1C=C2CCCC2=CC=1)C1(C(=O)N[C@@H]2CC[C@@H](CC2)C(O)=O)CCCC1 ZTWZVMIYIIVABD-OEMFJLHTSA-N 0.000 claims 2
- 229950004548 candoxatril Drugs 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- SHERAUCGTHRFCU-UHFFFAOYSA-N 1,3-dimethyl-7-(2-oxopropyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(CC(=O)C)C=1N1CCNCC1 SHERAUCGTHRFCU-UHFFFAOYSA-N 0.000 claims 1
- ARAFEULRMHFMDE-UHFFFAOYSA-N 1,3-oxazolidine-2,5-dione Chemical compound O=C1CNC(=O)O1 ARAFEULRMHFMDE-UHFFFAOYSA-N 0.000 claims 1
- FJJDFWFMTJCZBG-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-8-piperazin-1-ylpurin-7-yl)ethyl 3,4,5-trimethoxybenzoate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OCCN2C=3C(=O)N(C)C(=O)N(C)C=3N=C2N2CCNCC2)=C1 FJJDFWFMTJCZBG-UHFFFAOYSA-N 0.000 claims 1
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical compound O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 claims 1
- OZJASCJKXWVJDK-UHFFFAOYSA-N 3-methyl-7-(1-phenylethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1CNCCN1C1=NC=2N(C)C(=O)NC(=O)C=2N1C(C)C1=CC=CC=C1 OZJASCJKXWVJDK-UHFFFAOYSA-N 0.000 claims 1
- ZRSJKBZMIQCRAV-UHFFFAOYSA-N 3-methyl-7-(3-methylbutyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CCC(C)C)C=1N1CCNCC1 ZRSJKBZMIQCRAV-UHFFFAOYSA-N 0.000 claims 1
- URWZRCBFOLIMBX-UHFFFAOYSA-N 3-methyl-7-(3-phenylpropyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CCCN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCNCC1 URWZRCBFOLIMBX-UHFFFAOYSA-N 0.000 claims 1
- NCBQWTNHQFIYCS-UHFFFAOYSA-N 3-methyl-7-[(3-methylphenyl)methyl]-8-piperazin-1-ylpurine-2,6-dione Chemical compound CC1=CC=CC(CN2C=3C(=O)NC(=O)N(C)C=3N=C2N2CCNCC2)=C1 NCBQWTNHQFIYCS-UHFFFAOYSA-N 0.000 claims 1
- UTGRHIJKSXXDBN-UHFFFAOYSA-N 3-methyl-8-piperazin-1-yl-1,7-dipropylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)N(CCC)C(=O)C=2N(CCC)C=1N1CCNCC1 UTGRHIJKSXXDBN-UHFFFAOYSA-N 0.000 claims 1
- PSTDNERGQHJGIB-UHFFFAOYSA-N 3-methyl-8-piperazin-1-yl-7-propylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CCC)C=1N1CCNCC1 PSTDNERGQHJGIB-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- ZGZLYKUHYXFIIO-UHFFFAOYSA-N 5-nitro-2h-tetrazole Chemical compound [O-][N+](=O)C=1N=NNN=1 ZGZLYKUHYXFIIO-UHFFFAOYSA-N 0.000 claims 1
- WMQWNGOCKCYSAY-UHFFFAOYSA-N 7-[(2-chlorophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=C(Cl)C=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCNCC1 WMQWNGOCKCYSAY-UHFFFAOYSA-N 0.000 claims 1
- NUQFSJZWLOJBLL-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCNCC1 NUQFSJZWLOJBLL-UHFFFAOYSA-N 0.000 claims 1
- DJABCRUQDNAHBQ-YCRREMRBSA-N 7-[(e)-3-chlorobut-2-enyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(C\C=C(Cl)/C)C=1N1CCNCC1 DJABCRUQDNAHBQ-YCRREMRBSA-N 0.000 claims 1
- YOZCVGNKCHWWJJ-ONEGZZNKSA-N 7-[(e)-but-2-enyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(C/C=C/C)C=1N1CCNCC1 YOZCVGNKCHWWJJ-ONEGZZNKSA-N 0.000 claims 1
- WNVROUIPADYYDI-UHFFFAOYSA-N 7-[2-hydroxy-2-(4-nitrophenyl)ethyl]-3-methyl-8-piperazin-1-yl-8,9-dihydropurine-2,6-dione Chemical compound C1=2C(=O)NC(=O)N(C)C=2NC(N2CCNCC2)N1CC(O)C1=CC=C([N+]([O-])=O)C=C1 WNVROUIPADYYDI-UHFFFAOYSA-N 0.000 claims 1
- LRUXRWIHRNWCMG-UHFFFAOYSA-N 7-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C1=CC(OC)=CC=C1OCC(O)CN1C(C(=O)NC(=O)N2C)=C2N=C1N1CCNCC1 LRUXRWIHRNWCMG-UHFFFAOYSA-N 0.000 claims 1
- OSWQQKHGTFZUND-UHFFFAOYSA-N 7-benzyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound C=1C=CC=CC=1CN1C=2C(=O)NC(=O)N(C)C=2N=C1N1CCNCC1 OSWQQKHGTFZUND-UHFFFAOYSA-N 0.000 claims 1
- XARYHVKQXCTWDU-UHFFFAOYSA-N 7-butyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CCCC)C=1N1CCNCC1 XARYHVKQXCTWDU-UHFFFAOYSA-N 0.000 claims 1
- FDYKRGIGKFPKEU-UHFFFAOYSA-N 7-ethyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CC)C=1N1CCNCC1 FDYKRGIGKFPKEU-UHFFFAOYSA-N 0.000 claims 1
- GHMYMBNVKKTJGK-UHFFFAOYSA-N 7-heptyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CCCCCCC)C=1N1CCNCC1 GHMYMBNVKKTJGK-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010030124 Oedema peripheral Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042674 Swelling Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000005133 alkynyloxy group Chemical group 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 210000000544 articulatio talocruralis Anatomy 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000014471 histiocytoid cardiomyopathy Diseases 0.000 claims 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 1
- 229940091173 hydantoin Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200047 | 2002-01-11 | ||
| US34833202P | 2002-01-14 | 2002-01-14 | |
| PCT/DK2003/000017 WO2003057200A2 (en) | 2002-01-11 | 2003-01-13 | Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005513165A JP2005513165A (ja) | 2005-05-12 |
| JP2005513165A5 true JP2005513165A5 (enExample) | 2006-03-02 |
Family
ID=26069126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003557558A Withdrawn JP2005513165A (ja) | 2002-01-11 | 2003-01-13 | 糖尿病、高血圧、慢性心不全および体液貯留状態の治療のための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20030236272A1 (enExample) |
| EP (1) | EP1496877B1 (enExample) |
| JP (1) | JP2005513165A (enExample) |
| AT (1) | ATE409466T1 (enExample) |
| AU (1) | AU2003201274A1 (enExample) |
| DE (1) | DE60323823D1 (enExample) |
| WO (1) | WO2003057200A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| MXPA03007349A (es) * | 2001-02-24 | 2003-12-04 | Boehringer Ingelheim Pharma | Derivados de xantina, su preparacion y su empleo como medicamentos. |
| US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
| WO2003024965A2 (en) * | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| AU2003226913A1 (en) * | 2002-04-04 | 2003-10-20 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
| WO2003101992A1 (en) * | 2002-05-31 | 2003-12-11 | Schering Corporation | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DK1532149T3 (da) * | 2002-08-21 | 2010-05-10 | Boehringer Ingelheim Pharma | 8-[3-amino-piperiden-1-yl]-xanthiner, fremstilling deraf og anvendelse deraf som lægemiddel |
| US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| DE10238470A1 (de) * | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US7495005B2 (en) | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
| US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| DE10254304A1 (de) | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| KR20050122220A (ko) | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
| EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| KR20060041309A (ko) | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| KR20140089408A (ko) | 2003-11-17 | 2014-07-14 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
| DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| SI1715893T1 (sl) | 2004-01-20 | 2009-12-31 | Novartis Pharma Ag | Direktna kompresijska formulacija in postopek |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004009039A1 (de) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7393847B2 (en) | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
| EA013427B1 (ru) | 2004-03-15 | 2010-04-30 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы дипептидилпептидазы |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7179809B2 (en) * | 2004-04-10 | 2007-02-20 | Boehringer Ingelheim International Gmbh | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions |
| US7439370B2 (en) | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
| JP2008501714A (ja) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| EP1794120B1 (en) | 2004-07-23 | 2012-04-11 | Nuada, LLC | Peptidase inhibitors |
| AU2005271403A1 (en) * | 2004-08-03 | 2006-02-16 | Biorexis Pharmaceutical Corporation | Combination therapy using transferrin fusion proteins comprising GLP-1 |
| DE102004043944A1 (de) | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| CA2587499A1 (en) * | 2004-11-18 | 2006-05-26 | Schering Corporation | Methods of using pde v inhibitors for the treatment of congestive heart failure |
| EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7300494B2 (en) * | 2005-02-24 | 2007-11-27 | Hamilton Sundstrand Corporation | On-board inert gas generation system with compressor surge protection |
| CA2612217A1 (en) | 2005-06-15 | 2006-12-21 | Cambridge Enterprise Limited | Anti-inflammatory agents |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PT1942898E (pt) | 2005-09-14 | 2011-12-20 | Takeda Pharmaceutical | Inibidores da dipeptidilpeptidase para o tratamento da diabetes |
| CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
| JP5072848B2 (ja) * | 2005-09-20 | 2012-11-14 | ノバルティス アーゲー | 低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用 |
| WO2007050485A2 (en) * | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| WO2008017670A1 (en) | 2006-08-08 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
| BRPI0716971A2 (pt) * | 2006-09-13 | 2013-10-15 | Takeda Pharmaceutical | Uso de 2-6(3-amino-piperini-l-il)-3-metil-2,4-dioxo-3,4-dihidro-2 h-pirimidin-1ilmetil-4-fluoro-benxonitrila |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| MX2009004627A (es) * | 2006-11-01 | 2009-05-22 | Novartis Ag | Uso de inhibidores de dipeptidil-peptidasa iv para prevenir, demorar, o reducir la presentacion de edema. |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| CA2696579C (en) * | 2007-08-17 | 2017-01-24 | Boehringer Ingelheim International Gmbh | Purine derivatives for use in the treatment of fab-related diseases |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| MY164581A (en) * | 2008-08-15 | 2018-01-15 | Boehringer Ingelheim Int | Purin derivatives for use in the treatment of fab-related diseases |
| MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| EP2395983B1 (en) | 2009-02-13 | 2020-04-08 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| CN106975074A (zh) | 2010-06-24 | 2017-07-25 | 勃林格殷格翰国际有限公司 | 糖尿病治疗 |
| JP6065172B2 (ja) * | 2010-10-22 | 2017-01-25 | 国立大学法人名古屋大学 | 微小血管障害又はその関連疾患のバイオマーカー |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| PH12014500137A1 (en) | 2011-07-15 | 2017-08-18 | Boehringer Ingelheim Int | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| CN106188058B (zh) * | 2015-05-29 | 2020-11-06 | 江苏天士力帝益药业有限公司 | 黄嘌呤衍生物 |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US202560A (en) * | 1878-04-16 | Improvement in combined carriage and chair | ||
| KR880007441A (ko) * | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| US5508272A (en) * | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| US6569832B1 (en) * | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| US6380398B2 (en) * | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| US6509330B2 (en) * | 2000-02-17 | 2003-01-21 | Bristol-Myers Squibb Company | Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors |
| WO2002059343A2 (en) * | 2000-10-31 | 2002-08-01 | Vanderbilt University | Biological markers and diagnostic tests for angiotensin converting enzyme inhibitor- and vasopeptidase inhibitor-associated angioedema |
-
2003
- 2003-01-13 AU AU2003201274A patent/AU2003201274A1/en not_active Abandoned
- 2003-01-13 WO PCT/DK2003/000017 patent/WO2003057200A2/en not_active Ceased
- 2003-01-13 EP EP03729217A patent/EP1496877B1/en not_active Expired - Lifetime
- 2003-01-13 JP JP2003557558A patent/JP2005513165A/ja not_active Withdrawn
- 2003-01-13 DE DE60323823T patent/DE60323823D1/de not_active Expired - Fee Related
- 2003-01-13 AT AT03729217T patent/ATE409466T1/de not_active IP Right Cessation
- 2003-04-23 US US10/421,465 patent/US20030236272A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005513165A5 (enExample) | ||
| US9951075B2 (en) | Pteridines useful as HCV inhibitors and methods for the preparation thereof | |
| US10131671B2 (en) | Organic compounds | |
| JP2017523219A5 (enExample) | ||
| ES2532210T3 (es) | Métodos para el tratamiento concomitante de teofilina y febuxostat | |
| AU2018212614B2 (en) | Pharmaceutical compositions for combination therapy | |
| RU2002111005A (ru) | Производные нафтиридина | |
| AR035676A1 (es) | Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina | |
| JP2003515523A5 (enExample) | ||
| JP2013136596A (ja) | 白血病の処置のためのピリミジルアミノベンズアミド化合物との組合せでのｃ−Ｓｒｃ阻害剤の使用 | |
| CN115485027A (zh) | 冠状病毒感染引起的化学感觉功能障碍的治疗 | |
| SK6552003A3 (en) | Condensed purine derivatives as A1 adenosine receptor antagonists and process for the preparation thereof | |
| US9546175B2 (en) | Organic compounds | |
| RU2005137571A (ru) | Новые производные диазабициклононена | |
| KR20110093841A (ko) | 자가면역 질환의 치료를 위한 ｄｈｏｄｈ 억제제 및 메토트렉세이트를 포함하는 조합 요법 | |
| RU2004114239A (ru) | Производные пиримидина | |
| RU2005137174A (ru) | Азабициклононеновые производные | |
| JPWO2020076996A5 (enExample) | ||
| RS107404A (sr) | Metod lečenja ishemične povrede izazvane poremećajem perfuzije upotrebom antagonista adenozinskog receptora | |
| RU2003122189A (ru) | Сульфамидотиенопиримидины | |
| CN102481298A (zh) | 用于预防或治疗风湿性关节炎的含有瑞巴派特的药物组合物 | |
| RU2005137184A (ru) | Новые производные тропана | |
| US20230147835A1 (en) | Methods of treating systemic sclerosis | |
| JP2005500400A5 (enExample) | ||
| JP2008505938A5 (enExample) |